Exicon Co., Ltd. — Capital/Financing Update 2015

Dec 17, 2015

Copenhagen, 2015-12-17 09:12 CET (GLOBE NEWSWIRE) -- Exiqon A/S, listed on
Nasdaq Copenhagen (‘EXQ’), today announced that the recently issued senior
secured notes in the amount of DKK 40 million (‘Note’) will be admitted to
trading at First North Bond Market effective as of 18 December 2015. The terms
and conditions pertaining to the Note and a company description are enclosed
and may be found at: http://www.exiqon.com/investor/FirstNorthBondMarketIssue

Additional information

Lars Kongsbak, CEO, mobile phone: +45 4090 2101

Hans Henrik Chrois Christensen, CFO, mobile phone: +45 4090 2131

About Exiqon

Exiqon operates in two business areas: Exiqon Life Sciences, a leading provider
of flexible solutions for RNA analysis. Exiqon’s research products are used by
academia, biotech and pharmaceutical companies around the world to make
groundbreaking discoveries about the correlation between gene activity and the
development of cancer and other diseases. Exiqon Diagnostics collaborates with
pharmaceutical and diagnostic companies to develop novel molecular diagnostic
tests for early detection of diseases, which can help physicians make treatment
decisions based on the tools developed by Exiqon Life Sciences. Exiqon is
listed on NASDAQ in Copenhagen. For more information about us, please visit
www.exiqon.com